C-reactive protein level indicates AMD risk

Article

People with high blood levels of C-reactive protein may be at higher risk of developing age-related macular degeneration.

People with high blood levels of C-reactive protein may be at higher risk of developing age-related macular degeneration (AMD), according to a report published in October issue of Archives of Ophthalmology.

Sharmila S. Boekhoorn and colleagues from the Erasmus Medical Centre, Rotterdam, the Netherlands collected blood samples and took photographs of the eyes of more than 4,900 people at risk from AMD and followed the group for an average of 7.7 years. During this period, 658 subjects were diagnosed with AMD; 561 with initial stage AMD and 97 with advanced AMD.

It was found that as a person's C-reactive protein level increased the person became more and more likely to develop AMD.

The researchers suggest that lowering C-reactive protein levels may help decrease the risk of developing AMD.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.